# US 6,653,354 B2 · NMDA antagonist comprising xenon

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,653,354 B2
- Document ID: US6653354B2
- Status: Granted
- Kind: B2
- Application number: 09/881,178
- Filed: 2001-06-14
- Published: 2002-06-06
- Granted: 2003-11-25
- Earliest claimed: 1999-07-29
- Assignees: Protexeon Limited
- Inventors: Nicholas Peter Franks; Mervyn Maze
- Web page: https://patentgrep.com/patent/US6653354B2

## CPC

- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to the use of xenon as a neuroprotectant and/or as an inhibitor of synaptic plasticity. In a preferred aspect, the xenon acts as an NMDA antagonist. The present invention also provides a method of reducing the level of activation of the NMDA receptors in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon, wherein said reduction achieves neuroprotection and/or an inhibition of synaptic plasticity. A further embodiment of the invention provides a pharmaceutical composition for providing neuroprotection and/or inhibition of synaptic plasticity, together with a process for the preparation thereof. Another aspect of the invention relates to a pharmaceutical composition suitable for providing neuroprotection, inhibiting synaptic plasticity or relieving neuropathic pain, said composition comprising xenon and a GABAergic agent admixed with a pharmaceutically acceptable carrier, excipient or diluent.

## Claims

### Claim 1

A method of providing neuroprotection, inhibiting synaptic plasticity, or for relieving neuropathic pain in a mammal the method comprising administering to a mammal in need thereof a therapeutically effective amount of xenon.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the xenon is an NMDA receptor antagonist.

### Claim 3 (depends on 1)

A method according to claim 1 wherein the xenon is used in combination with a GABAergic agent.

### Claim 4 (depends on 1)

A method according to claim 1 wherein the GABAergic agent is selected from the group consisting of a benzodiazepine, propofol, isoflurane, and mixtures thereof.

### Claim 5

A method for modulating the activity of an NMDA receptor in a mammal in need thereof comprising administering to the mammal xenon in amounts effective to modulate the activity of said receptor.

### Claim 6 (depends on 5)

A method according to claim 5 wherein the xenon is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 7 (depends on 5)

A method according to claim 5 wherein the xenon is administered in combination with a GABAergic agent.

### Claim 8 (depends on 7)

A method according to claim 7 wherein the GABAergic agent is selected from the group consisting of a benzodiazepine, propofol, isoflurane, and mixtures thereof.

### Claim 9 (depends on 5)

A method according to claim 5 where the mammal is treated for a condition associated with NMDA receptor activity.

### Claim 10 (depends on 5)

A method according to claim 5 wherein the mammal is treated for a condition associated with NMDA receptor activation.

### Claim 11 (depends on 5)

A method according to claim 5 wherein the xenon reduces the level of activation of the NMDA receptor.

### Claim 12 (depends on 2)

A method according to claim 2, wherein the administration of xenon provides neuroprotection to the mammal in need thereof.

### Claim 13 (depends on 2)

A method according to claim 2, wherein the administration of xenon inhibits synaptic plasticity in the mammal in need thereof.

### Claim 14 (depends on 2)

A method according to claim 2, wherein the administration of xenon relieves neuropathic pain in the mammal in need thereof.

### Claim 15 (depends on 11)

A method according to claim 11, wherein administration of xenon to the mammal in need thereof provides neuroprotection to the mammal.

### Claim 16 (depends on 11)

A method according to claim 11, wherein the administration of xenon inhibits synaptic plasticity in the mammal in need thereof.

### Claim 17 (depends on 11)

A method according to claim 11, wherein the administration of xenon relieves neuropathic pain in the mammal in need thereof.
